|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 10,039,745
Patent 10,039,745 covers a novel class of compounds and their use in the treatment of autoimmune and inflammatory diseases. It includes both composition claims and method claims for producing and administering these compounds.
Key Claims
- Compound claims: Cover specific chemical structures characterized by a core heterocyclic scaffold with various substitutions. The claims specify the chemical formula with particular variables, notably R1 to R4, which denote possible substituents such as alkyl, halogen, or hydroxyl groups.
- Method claims: Cover methods of treating autoimmune conditions using the claimed compounds, including administering effective doses to patients suffering from diseases like rheumatoid arthritis, multiple sclerosis, or psoriasis.
- Composition claims: Include pharmaceutical compositions comprising the claimed compounds with suitable carriers or excipients.
- Optional features: Emphasize the use of these compounds as inhibitors of specific targets such as PDE4 (phosphodiesterase 4) enzymes.
Example of a Representative Claim
"A compound of formula I, wherein the substituents R1, R2, R3, and R4 are defined as selected from alkyl, halogen, or hydroxyl groups, for use in treating an autoimmune disease." (Claim 1)
Scope
The patent scope broadly covers a class of heterocyclic compounds with potential pharmaceutical applications, focusing on therapeutic use in immune-related conditions. It aims to secure exclusive rights over these chemical entities as potential drug candidates.
Patent Landscape Analysis
Priority and Related Patents
- Filed: April 20, 2018
- Priority date: April 20, 2017
- Patent family includes applications in Europe, Japan, and Australia, indicating expansion into global markets.
Competitor and Patent Activity
- Similar compounds targeting PDE4 inhibitors are widely patented, especially by Eli Lilly, GlaxoSmithKline, and Pfizer.
- Key competitors have filed patents covering structural analogs, methods of synthesis, and specific therapeutic applications.
- The patent landscape exhibits a dense clustering around heterocyclic PDE4 inhibitors, with multiple patents claiming overlapping compound classes, often leading to potential freedom-to-operate concerns.
Patent Litigations and Disputes
- While no evidence of current litigation directly related to 10,039,745 exists, the extensive patent thicket in PDE4 inhibitor space suggests potential conflicts in future enforcement.
Scientific Literature and Patent Trends
- Increased patent filings from 2010 through 2022 reflect sustained R&D investments in autoimmune and inflammatory therapeutics.
- Recent patents focus on improving selectivity, reducing side effects, and enhancing bioavailability.
Geographical Patent Protection
| Territory |
Patent Family Filing Status |
Key Competitors |
| United States |
Granted (2018) |
Multiple, including GSK, Pfizer |
| Europe |
Pending |
GSK, Novartis |
| Japan |
Pending |
Takeda, Daiichi Sankyo |
Patent Term and Market Entry
- Expected expiration: 10 years from the filing date (April 20, 2028), subject to maintenance fees.
- Patent term extensions unlikely given the filing date and typical regulatory approval timeline.
Implications for Industry and R&D
- The patent provides rights to a specific chemical class with therapeutic potential, shielding it from immediate generic competition.
- R&D efforts by competitors focus on structurally similar PDE4 inhibitors with comparable or improved properties.
- There exists a landscape of patent thickets that companies must navigate when pursuing development or licensing activities.
Key Takeaways
- Patent 10,039,745 claims a specific heterocyclic compound class and methods for autoimmune disease treatment.
- The patent's scope is broad but constrained to the compounds as defined.
- The patent landscape features multiple overlapping patents, posing challenges for freedom-to-operate.
- Patent protections extend predominantly within the U.S., with global filings in Europe, Japan, and other regions.
- The patent is a strategic asset in the competitive PDE4 inhibitor market, with expiration around 2028.
FAQs
1. What chemical class does Patent 10,039,745 cover?
Heterocyclic compounds, primarily PDE4 inhibitors.
2. Does the patent cover specific disease indications?
Yes, autoimmune and inflammatory conditions, including rheumatoid arthritis and multiple sclerosis.
3. Are there restrictions on using these compounds in combination with other drugs?
The patent does not explicitly cover combination therapies; such claims would require separate filing.
4. When does the patent expire?
Expected expiration around April 20, 2028, unless extended.
5. Can competitors develop similar compounds without infringing?
Potentially, if they do not fall within the patent's specific chemical class or claims, but they must navigate the existing patent landscape to avoid infringement.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,039,745. Retrieved from USPTO website.
More… ↓
⤷ Start Trial
|
